You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Antimicrobial Resistance (AMR)

Test Information
Home / Tests / Critical Infectious Diseases / Xpert MTB/RIF

Xpert® MTB/RIF

Accurate Detection of MTB and Rifampin Resistance Mutations

Xpert<sup>®</sup> MTB/RIF

The Need


Great challenges face the global community, including the United States, with the worldwide re-emergence of TB and increased number of multi-drug resistant TB (MDR-TB) cases. The need for fast and accurate TB diagnosis with indication  for drug resistance is greater than ever.

Current MTB diagnostic methods require weeks to deliver a definitive result. Delayed results reporting can lead to patients placed in respiratory isolation unnecessarily or put on ineffective therapies. AFB smear could provide faster turn-around time, but may be missing the true positive cases and patients may continue to spread MTB to others in the community, increasing the disease burden.

The Solution


Xpert® MTB/RIF, on-demand molecular testing — an ideal solution:

  • On-demand results that empowers physicians to manage patients effectively
  • As few as one negative result can be used in the decision  to remove patient from respiratory isolation
  • Simultaneous detection of both MTB and rifampin resistance mutations, which are markers for MDR-TB strain
  • Acceptable samples include raw or concentrated sediments prepared from induced or expectorated sputum

The Impact


Impact on Patient Isolation Pathway
“Test and Release” or “Test and Treat”

/Site Images/Tests/mtbrif-pathway-updated.png

* Refer to the Xpert MTB/RIF package insert for details
^ Example with one Xpert® MTB/RIF negative result
# MOTT: Mycobacteria Other Than Tuberculosis; DST: Drug Susceptibly Test
1. FDA. New data shows test can help physicians remove patients with suspected TB from isolation earlier. Press Release. 2015 Feb 12. Accessed Feb 2021. https://wayback.archive-it.org/7993/20180126103209/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434226.htm
2. WHO. WHO endorses new rapid tuberculosis test. Press Release. 2010 Dec 8. Accessed Feb 2021. http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/
3. CDC. A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. Accessed Feb 2021. http://www.cdc.gov/tb/publications/factsheets/PDF/XpertMTB-RIFAssayFactSheet_Final.pdf
4. Davis JL, et al. Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1551-9.
5. Lippincott CK, et al. Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States. Clin Infect Dis. 2014 Jul 15;59(2):186-92Workflow:3 Easy StepsUS-IVD. For In Vitro Diagnostic Use.231Pour

Ordering Info


Xpert® MTB/RIF

Standard 10-Test Kit

Catalog #: GXMTB/RIF-US-10
Back to Top